Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants. In a mid- to late-stage trial, Enflonsia reduced RSV-associated hospitalizations in infants more than 84% compared with a placebo. RSV can sometimes turn into serious lower respiratory infections like pneumonia, but the shot also reduced lower respiratory infections that needed medical attention by more than 60% compared with a placebo.